CNS metastasis in primary breast cancer

Expert Review of Anticancer Therapy

Volumn 7, Issue 11, 2007, Pages 1561-1566

  Sharma, Manish ^a   Abraham, Jame ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Breast cancer; Chemotherapy; CNS; Leptomeningeal; Metastasis; Radiotherapy

Indexed keywords

ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; CAPECITABINE; CISPLATIN; CORTICOSTEROID DERIVATIVE; CYTARABINE; DEXAMETHASONE; EFAPROXIRAL; LAPATINIB; METHOTREXATE; PACLITAXEL; RADIOSENSITIZING AGENT; TEMOZOLOMIDE; THIOTEPA; TOPOTECAN; TRASTUZUMAB;

BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN DISEASE; BRAIN METASTASIS; BRAIN RADIATION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER STAGING; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; CHEMOTHERAPY INDUCED EMESIS; CLINICAL FEATURE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE COMPARISON; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG PENETRATION; DRUG WITHDRAWAL; FATIGUE; GAMMA KNIFE RADIOSURGERY; HEART DISEASE; HUMAN; LEUKOENCEPHALOPATHY; LEUKOPENIA; LOW DRUG DOSE; MENINGEAL METASTASIS; MENINGITIS; MONOTHERAPY; NAUSEA; NEUTROPENIA; PATIENT CARE; PREVALENCE; REVIEW; SEIZURE; SIDE EFFECT; SOLID TUMOR; SPINAL CORD DISEASE; WHOLE BRAIN RADIATION;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS;

EID: 37349131258     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.7.11.1561     Document Type: Review

References (47)

1. DiStefano A, Yong Yap Y, Hortobagyi GN, Blumenschein GR. The natural history of breast cancer patients with brain metastases. Cancer 44, 1913-1918 (1979).
2. Zimm S, Wampler GL, Stablein D, Hazra T, Young HF. Intracerebral metastases in solid-tumor patients: natural history and results of treatment. Cancer 48, 384-394 (1981).
3. Boccardo F, Comelli G, De Menech R, Mina G, Zanardi S. Natural history and staging of brain metastases. Minerva Med. 75, 1369-1378 (1984).
4. Boogerd W, Vos VW, Hart AA, Baris G. Brain metastases in breast cancer; natural history, prognostic factors and outcome. J. Neurooncol. 15, 165-174 (1993).
5. Patanaphan V, Salazar OM, Risco R. Breast cancer: metastatic patterns and their prognosis. South. Med. J. 81, 1109-1112 (1988).
6. Bendell JC, Domchek SM, Burstein HJ et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97, 2972-2977 (2003).
7. Burstein HJ, Lieberman G, Slamon DJ, Winer EP, Klein P. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann. Oncol. 16, 1772-1777 (2005).
8. Gonzalez-Angulo AM, Cristofanilli M, Strom EA et al. Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment. Cancer 101, 1760-1766 (2004).
9. Taillibert S, Laigle-Donadey F, Chodkiewicz C, Sanson M, Hoang-Xuan K, Delattre JY. Leptomeningeal metastases from solid malignancy: a review. J. Neurooncol. 75, 85-99 (2005).
10. Kaal EC, Taphoorn MJ, Vecht CJ. Symptomatic management and imaging of brain metastases. J. Neurooncol. 75, 15-20 (2005).
11. Schellinger PD, Meinck HM, Thron A. Diagnostic accuracy of MRI compared with CCT in patients with brain metastases. J. Neurooncol. 44, 275-281 (1999).
12. Vecht CJ, Hovestadt A, Verbiest HB, van Vliet JJ, van Putten WL. Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day. Neurology 44, 675-680 (1994).
13. Khuntia D, Brown P, Li J, Mehta MP. Whole-brain radiotherapy in the management of brain metastasis. J. Clin. Oncol. 24, 1295-1304 (2006).
14. Borgelt B, Gelber R, Kramer S et al. The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int. J. Radiat. Oncol. Biol. Phys. 6, 1-9 (1980).
15. Murray KJ, Scott C, Greenberg HM et al. A randomized Phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: a report of the Radiation Therapy Oncology Group (RTOG) 9104. Int. J. Radiat. Oncol. Biol. Phys. 39, 571-574 (1997).
16. Patchell RA, Tibbs PA, Walsh JW et al. A randomized trial of surgery in the treatment of single metastases to the brain. N. Engl. J. Med. 322, 494-500 (1990).
17. Mintz AH, Kestle J, Rathbone MP et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 78, 1470-1476 (1996).
18. Noordijk EM, Vecht CJ, Haaxma-Reiche H et al. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int. J. Radiat. Oncol. Biol. Phys. 29, 711-717 (1994).
19. Patchell RA, Tibbs PA, Regine WF et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 280, 1485-1489 (1998).
20. Andrews DW, Scott CB, Sperduto PW et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III results of the RTOG 9508 randomised trial. Lancet 363, 1665-1672 (2004).
21. Mintz A, Perry J, Spithoff K, Chambers A, Laperriere N. Management of single brain metastasis: a practice guideline. Curr. Oncol. 14, 131-143 (2007).
22. Roos DE, Wirth A, Burmeister BH et al. Whole brain irradiation following surgery or radiosurgery for solitary brain metastases: mature results of a prematurely closed randomized Trans-Tasman Radiation Oncology Group trial (TROG 98.05). Radiother. Oncol. 80, 318-322 (2006).
23. Aoyama H, Shirato H, Tago M et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 295, 2483-2491 (2006).
24. Christodoulou C, Bafaloukos D, Linardou H et al. Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study. J. Neurooncol. 71, 61-65 (2005).
25. Rivera E, Meyers C, Groves M et al. Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer 107, 1348-1354 (2006).
26. Trudeau ME, Crump M, Charpentier D et al. Temozolomide in metastatic breast cancer (MBC): a Phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG). Ann. Oncol. 17, 952-956 (2006).
27. Abrey LE, Olson JD, Raizer JJ et al. A Phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J. Neurooncol. 53, 259-265 (2001).
28. Christodoulou C, Bafaloukos D, Kosmidis P et al. Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann. Oncol. 12, 249-254 (2001).
29. Addeo R, Caraglia M, Faiola V et al. Concomitant treatment of brain metastasis with whole brain radiotherapy (WBRT) and temozolomide (TMZ) is active and improves quality of life. BMC Cancer 7, 18 (2007).
30. Oberhoff C, Kieback DG, Wurstlein R et al. Topotecan chemotherapy in patients with breast cancer and brain metastases: results of a pilot study. Onkologie 24, 256-260 (2001).
31. Lorusso V, Galetta D, Giotta F et al. Topotecan in the treatment of brain metastases. A Phase II study of GOIM (Gruppo Oncologico dell'Italia Meridionale). Anticancer Res. 26, 2259-2263 (2006).
32. Kocher M, Eich HT, Semrau R, Guner SA, Muller RP. Phase I/II trial of simultaneous whole-brain irradiation and dose-escalating topotecan for brain metastases. Strahlenther Onkol. 181, 20-25 (2005).
33. Glantz MJ, Cole BF, Recht L et al. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J. Clin. Oncol. 16, 1561-1567 (1998).
34. Lassman AB, Abrey LE, Shah GD et al. Systemic high-dose intravenous methotrexate for central nervous system metastases. J. Neurooncol. 78, 255-260 (2006).
35. + breast cancer. J Clin. Oncol. 24, 503 (2006).
36. + breast cancer following trastuzurnab (H) based systemic therapy and cranial radiotherapy (RT). J. Clin. Oncol. 25, 1012 (2007).
37. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355, 2733-2743 (2006).
38. Suh JH, Stea B, Nabid A et al. Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases. J. Clin. Oncol. 24, 106-114 (2006).
39. Chamberlain MC. Neoplastic meningitis. J. Clin. Oncol. 23, 3605-3613 (2005).
40. Grossman SA, Finkelstein DM, Ruckdeschel JC, Trump DL, Moynihan T, Ettinger DS. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J. Clin. Oncol. 11, 561-569 (1993).
41. Jaeckle KA, Batchelor T, O'Day SJ et al. An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis. J. Neurooncol. 57, 231-239 (2002).
42. Glantz MJ, Jaeckle KA, Chamberlain MC et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin. Cancer Res. 5, 3394-3402 (1999).
43. Orlando L, Curigliano G, Colleoni M et al. Intrathecal chemotherapy in carcinomatous meningitis from breast cancer. Anticancer Res. 22, 3057-3059 (2002).
44. Kim DY, Lee KW, Yun T et al. Comparison of intrathecal chemotherapy for leptomeningeal carcinomatosis of a solid tumor: methotrexate alone versus methotrexate in combination with cytosine arabinoside and hydrocortisone. Jpn. J. Clin. Oncol. 33, 608-612 (2003).
45. Siegal T. Leptomeningeal metastases: rationale for systemic chemotherapy or what is the role of intra-CSF chemotherapy? J. Neurooncol. 38, 151-157 (1998).
46. Bokstein F, Lossos A, Siegal T. Leptomeningeal metastases from solid tumors: a comparison of two prospective series treated with and without intra-cerebrospinal fluid chemotherapy. Cancer 82, 1756-1763 (1998).
47. Boogerd W, van den Bent MJ, Koehler PJ et al. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. Eur. J. Cancer 40, 2726-2733 (2004).